Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery

CPT: Pharmacometrics and Systems Pharmacology

Volumn 3, Issue 9, 2014, Pages

  Leil, T A ^a   Frost, C ^a   Wang, X ^a   Pfister, M ^a,b,c   LaCreta, F ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Quantitative Solutions Inc   (United States)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN;

AGED; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BODY WEIGHT; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG RESPONSE; FEMALE; HIP ARTHROPLASTY; HUMAN; KIDNEY FUNCTION; KNEE ARTHROPLASTY; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK FACTOR; SIMULATION; VOLUME OF DISTRIBUTION;

EID: 84927938274     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2014.34     Document Type: Article

References (39)

1. Geerts, W.H. et al.; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133, 381S-453S (2008).
2. Hirsh, J., Bauer, K.A., Donati, M.B., Gould, M., Samama, M.M. & Weitz, J.I.; American College of Chest Physicians. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133, 141S-159S (2008).
3. Martel, N., Lee, J. & Wells, P.S. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106, 2710-2715 (2005).
4. Morris, T.A., Castrejon, S., Devendra, G. & Gamst, A.C. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis. Chest 132, 1131-1139 (2007).
5. Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M. & Palareti, G.; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133, 160S-198S (2008).
6. Harris, J.E. Interaction of dietary factors with oral anticoagulants: review and applications. J. Am. Diet. Assoc. 95, 580-584 (1995).
7. Hawkins, D. Limitations of traditional anticoagulants. Pharmacotherapy 24, 62S-65S (2004).
8. Rewinkel, J.B. & Adang, A.E. Strategies and progress towards the ideal orally active thrombin inhibitor. Curr. Pharm. Des. 5, 1043-1075 (1999).
9. Frost, C. et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br. J. Clin. Pharmacol. 75, 476-487 (2013).
10. Pinto, D.J. et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)- 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J. Med. Chem. 50, 5339-5356 (2007).
11. Wong, P.C. et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J. Thromb. Haemost. 6, 820-829 (2008).
12. Bristol-Myers Squibb. Eliquis' (apixaban tablets) Prescribing information. (2013).
13. Frost, C. et al. Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation [abstract 148]. J. Clin. Pharmacol. 48, 1132 (2008).
14. Frost, C. et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. 76, 776-786 (2013).
15. Vakkalagadda, B. et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa [abstract]. J. Clin. Pharmacol. 49, 1091-1130 (2009).
16. Zhang, D. et al. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats. Drug Metab. Dispos. 41, 906-915 (2013).
17. Raghavan, N. et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab. Dispos. 37, 74-81 (2009).
18. Lassen, M.R., Raskob, G.E., Gallus, A., Pineo, G., Chen, D. & Hornick, P.; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375, 807-815 (2010).
19. Lassen, M.R., Gallus, A., Raskob, G.E., Pineo, G., Chen, D. & Ramirez, L.M.; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N. Engl. J. Med. 363, 2487-2498 (2010).
20. Lassen, M.R., Raskob, G.E., Gallus, A., Pineo, G., Chen, D. & Portman, R.J. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N. Engl. J. Med. 361, 594-604 (2009).
21. Kennedy, J.M. & Riji, A.M. Effects of surgery on the pharmacokinetic parameters of drugs. Clin. Pharmacokinet. 35, 293-312 (1998).
22. Grosflam, J.M., Wright, E.A., Cleary, P.D. & Katz, J.N. Predictors of blood loss during total hip replacement surgery. Arthritis Care Res. 8, 167-173 (1995).
23. Leil, T.A., Feng, Y., Zhang, L., Paccaly, A., Mohan, P. & Pfister, M. Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin. Pharmacol. Ther. 88, 375-382 (2010).
24. Bristol-Myers Squibb and Pfizer EEIG. Eliquis' (apixaban tablets) Summary of product characteristics. .
25. Pineo, G.F. et al. Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. J. Thromb. Haemost. 11, 444-451 (2013).
26. Mandema, J.W., Boyd, R.A. & DiCarlo, L.A. Therapeutic index of anticoagulants for prevention of venous thromboembolism following orthopedic surgery: a dose-response meta-analysis. Clin. Pharmacol. Ther. 90, 820-827 (2011).
27. Pineo, G.F. et al. Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. J. Thromb. Haemost. 11, 444-451 (2013).
28. Chang, M. et al. Apixaban pharmacokinetics and pharmacodynamics in subjects with renal impairment. 2012 ACCP Annual Meeting (Abstract 1381212). Clin Pharmacol Drug Dev. 1, 185-186 (2012).
29. Frost, C., Nepal, S., Barrett, Y. & LaCreta, F. Effects of age and gender on the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of apixaban. J. Thromb. Haemost. 7, PP-MO-407 (2009).
30. Lassen, M.R., Davidson, B.L., Gallus, A., Pineo, G., Ansell, J. & Deitchman, D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J. Thromb. Haemost. 5, 2368-2375 (2007).
31. Levine, M.N. et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J. Thromb. Haemost. 10, 807-814 (2012).
32. Cui, Y. et al. Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects. Clin. Pharmacol. 5, 177-184 (2013).
33. Upreti, V.V. et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br. J. Clin. Pharmacol. 76, 908-916 (2013).
34. Yamahira, N. et al. A placebo-controlled, ascending multiple-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of apixaban in healthy Japanese subjects. (A637). Can. J. Clin. Pharmacol. 15, e420-e781 (2008).
35. Lavielle, M. & Mentré, F. Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. J. Pharmacokinet. Pharmacodyn. 34, 229-249 (2007).
36. Cockcroft, D.W. & Gault, M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16, 31-41 (1976).
37. Yu, Z., Nepal, S., Bragat, A., Shenker, A. & Frost, C. Single dose apixaban pharmacokinetics and pharmacodynamics in healthy male Japanese and Caucasian subjects (A647). Can. J. Clin. Pharmacol. 15, e420-e781 (2008).
38. Gibiansky, L. & Gastonguay, M.R. R/NONMEM Toolbox for simulation from posterior parameter (uncertainty) distributions (Abstract 958). PAGE. (2006).
39. Barrett, Y.C. et al. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. Thromb. Haemost. 107, 916-924 (2012).